Shareholders Reject Critical Capital Raise and Equity Plan Proposals Amidst Going Concern Warning

summarizeSummary

Silexion Therapeutics shareholders rejected proposals to increase authorized share capital and expand the equity incentive plan, hindering the company's ability to raise much-needed funds amidst a "going concern" warning.

check_boxKey Events · Financing and Capital Events · SLXN

• Share Capital Increase Rejected

  Shareholders voted against increasing the authorized share capital by 50,000,000 ordinary shares, which would have expanded the total from 9,000,000 to 59,000,000 shares.

• Equity Plan Expansion Denied

  A proposal to amend the 2024 Equity Incentive Plan to increase the annual 'evergreen' provision from 5% to 10% of issued and outstanding shares was also not approved.

• Impact on Capital Raising

  The rejection of the authorized share capital increase directly impedes the company's ability to issue new equity, a critical mechanism for addressing its previously disclosed 'going concern' warning and urgent cash needs.

• Meeting Reconvened

  The extraordinary general meeting, previously adjourned on March 16, 2026, due to a lack of quorum, was reconvened on March 23, 2026, where a quorum was eventually established to conduct the vote.

auto_awesomeAnalysis · SLXN · Life Sciences

The rejection of both proposals, particularly the increase in authorized share capital, significantly exacerbates Silexion Therapeutics' already precarious financial situation. Following a recent "going concern" warning and a stated need for capital, this outcome severely limits the company's ability to raise funds through equity issuance, increasing the risk of further financial distress or potential bankruptcy. This negative development occurs while the stock is trading near its 52-week low, underscoring the challenging environment. Investors should monitor for alternative financing strategies or further updates on the company's operational runway.